Chimeric Therapeutics Limited (ASX:CHM)

Market Cap	9.76M
Revenue (ttm)	12.68M
Net Income (ttm)	-10.43M
Shares Out	3.25B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,786,754
Average Volume	9,139,055
Open	0.0030
Previous Close	0.0020
Day's Range	0.0030 - 0.0030
52-Week Range	0.0020 - 0.0160
Beta	1.55
RSI	48.11
Earnings Date	Aug 29, 2025

About Chimeric Therapeutics

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17 CAR T cell therapy that is in Phase I/II multi-centre clinical trials for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a Chlorotoxin CAR T cell therapy, which is in phase Ia/IIb clinical trials for patients with recurrent or progressive Glioblastoma, as well as in preclinical trials for MMP2 express...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CHM

Financial Performance

In 2025, Chimeric Therapeutics's revenue was 12.68 million, an increase of 70.09% compared to the previous year's 7.46 million. Losses were -10.43 million, -16.76% less than in 2024.